Global Community

Exceptional investments are often hiding behind familiar labels. Hotel101 Global Holdings may appear, at first glance, to be just another hotel company.Read more

Rating: High-Quality Compounder / Buy on pullbacks Style: Infrastructure-led secular grower Core debate: Is Quanta simply an expensive contractor riding an unusually strong capex cycle, or is it the best-positioned execution platform for a multi-year grid, electrification, and AI-power buildout that deserves a premium multiple? Executive view Quanta is one of the clearest “picks-and-shovels” beneficiaries of the U.S. power infrastructure supercycle.Read more

🪙 Polymetals Resources Ltd (ASX:POL) Polymetals Resources (ASX:POL) is an Australian polymetal producer/restart story centered on the Endeavor silver–zinc–lead mine in the Cobar Basin, NSW. Unlike a “pure silver” discovery play, Endeavor’s economics are driven by multi-metal concentrates (Zn + Pb with Ag credits) and the operational ramp to steadier shipments/cashflow.Read more

Fidson Healthcare Plc - Narrative At its core, Fidson Healthcare Plc is a company benefiting from a simple but powerful trend: Nigeria is steadily shifting toward producing more of its own medicines. As this transition plays out, companies that already have the capacity, regulatory footing, and distribution network in place are likely to pull ahead—and FIDSON fits that profile.Read more

Catalysts Recent success in a phase IIIa trial showed once-daily doses of oral semaglutide demonstrated a statistically significant and superior reduction in HbA1c by 0.83% versus placebo at 26 weeks for adolescents with Type II diabetes. Based on the study data, NVO intends to seek regulatory approval for oral semaglutide in adolescents aged 10 to 17 with T2D for both Rybelsus and oral Ozempic in the U.S. and the EU in the second half of the year.Read more

I believe Cobre Limited (ASX) is currently being undervalued by the market, which still sees it as a turnaround story. However, the Sierra Atacama acquisition presents an exciting opportunity for the company to establish itself as a credible copper producer in Chile.Read more

️ Business Overview Key Metrics Total: -2.5/17 +1 ✅ Projected Operating Margin: 12% +0 ⚠️ Projected 5-Year Revenue CAGR: 8% +0 ⚠️ Last 5-Year ROIC: 9.83% +0 ⚠️ Estimated Cost of Capital: 9.83% (around ROIC) -1 ❌ Last 5-Year Shares Outstanding CAGR: +0.50% +1 ✅ Projected 5-Year EPS CAGR: 12.36% +1 ✅ Projected 5-Year Dividend CAGR: 11.63% -1.5 ❌ Estimated Debt Rating: B1 -2 ❌❌ Morningstar Moat: None -1 ❌ Morningstar Uncertainty: High During the 2030 projections, the Mota-Engil management projected the following for the future of the company: 2026 Revenue Growth : to accelerate to 10-15% Operating Margin to be sustained around 11-12% Net Margin to be maintained around 2.5-3% EPS to grow from 0.43 euros to 0.47-0.60 2030 Revenue Growth 9.000 million by 2030, representing a 10% CAGR Operating Margin to expand into >= 13% Net Margin to expand into >=4% EPS to grow from 0.43 euros to 0.55-1.17 (this are my expectations, given my lower to higher assumptions, presented later on during this valuation). To be honest this confident and overall good projections by the management took me by surprise and I reavaluated my position on the company.Read more

Investment Thesis At $58 the FY2025 FCF yield is ~13.8%, pricing in significant permanent impairment — if transformation spend proves genuinely temporary, the stock is cheap relative to normalized earnings power Core switching costs remain intact: Financial Solutions posted 38% GAAP operating margins even in the trough quarter, confirming the underlying contract economics have not deteriorated Clover Merchant organic revenue held at only -1% in Q1 despite macro pressure, suggesting volume share is stable and the SMB platform is not losing ground to Square or Toast May 14 Investor Day is a near-term catalyst — credible medium-term FCF and margin targets could re-rate the stock materially from current levels Buyback suspension preserves balance sheet flexibility during peak transformation spend; resumption at $58 would be highly accretive and is a logical 2027 capital allocation move if FCF recovers Risk Considerations Q1 2026 FCF of $259M annualizes to ~$1B against $29.4B in net debt — if the trough extends into 2027, leverage becomes a genuine constraint and the equity cushion narrows further Financial Solutions organic revenue declined 6% in Q1, the steepest rate in the dataset, with no disclosed inflection catalyst before Investor Day The One Fiserv transformation is consuming cash at an accelerating rate ($95M in Q1 transformation payments alone) with no demonstrated financial results yet — execution risk on a multi-year AI and platform modernization is high Buyback suspension removes the ~6% annual share count reduction that was the primary EPS accretion mechanism, leaving the forward earnings story dependent entirely on organic recoveryRead more

98% of pancreatic cancer patients in Phase II study generated powerful immune responses to the KRAS antigens. Median T-cell immune response above threshold was 44-fold.Read more